Porous graphitic carbon based chromatography hyphenated with mass spectrometry: A new strategy for profiling thiopurine nucleotides in patients with inflammatory bowel diseases.
Azathioprine
Inflammatory bowel diseases
Mass spectrometry
Porous graphitic carbon based chromatography
Therapeutic drug monitoring
Thiopurine nucleotides
Journal
Analytica chimica acta
ISSN: 1873-4324
Titre abrégé: Anal Chim Acta
Pays: Netherlands
ID NLM: 0370534
Informations de publication
Date de publication:
15 Nov 2020
15 Nov 2020
Historique:
received:
03
07
2020
revised:
19
08
2020
accepted:
29
08
2020
entrez:
6
11
2020
pubmed:
7
11
2020
medline:
15
5
2021
Statut:
ppublish
Résumé
Thiopurine (TP) treatment is discontinued in up to 30% of patients suffering from inflammatory bowel diseases (IBD) due to various adverse effects. Therapeutic drug monitoring of biologically active TP metabolites, i.e. thiopurine nucleotides (TPN), can help to optimize the efficacy and safety of the TP treatment. In our work, a novel strategy for TPN profiling, based on a porous graphitic carbon (PGC) chromatography, was developed. The validated PGC-MS method was compared with ion-exchange LC-MS, a currently leading analytical approach established for the determination of TPN. The innovative approach enabled an enhancement of several key performance parameters demanded in a clinical routine use, namely (i) selectivity (time- and mass-recognition of all 12 TPN in one run), (ii) sensitivity (2-5-fold increase in intensities of the analytical signals), (iii) sample throughput (25% shorter analysis time). Application of the novel TPN profiling strategy to a pilot clinical study (12 patients) revealed significantly higher levels of 6-methylthioguanine 5'-diphosphate (MeTGDP) in non-responsive IDB patients treated with azathioprine. Some other TPN are very close to the critical level (p = 0.05) and they will need larger groups of IBD patients to confirm definitively their relevance. In conclusion, the developed PGC-MS method represents a significant improvement to currently available methods for detailed profiling of TPN and its use in bigger clinical studies should lead to a better understanding of the relationship between TPN profiles and therapeutic outcome.
Identifiants
pubmed: 33153610
pii: S0003-2670(20)30911-9
doi: 10.1016/j.aca.2020.08.064
pii:
doi:
Substances chimiques
Nucleotides
0
Carbon
7440-44-0
Graphite
7782-42-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
64-73Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.